ArticleBehavioral and brain functions : BBF2016
Venlafaxine ameliorates the depression-like behaviors and hippocampal S100B expression in a rat depression model.
Article in Behavioral and brain functions : BBF, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Eukaryotic initiation factor 4E: a key factor of traumatic stress-induced depression-related cognitive decline at different age.Translational psychiatry · 2026Article
- Promising Antidepressant Potential: The Role of Lactobacillus rhamnosus GG in Mental Health and Stress Response.Probiotics and antimicrobial proteins · 2025Article
- Gastrodin inhibits reactive astrocyte-mediated inflammation in hypoxic-ischemic brain damage through S100B/RAGE-Smad3 signaling.Acta biochimica et biophysica Sinica · 2025Article
- Combination of low doses of mirtazapine plus venlafaxine produces antidepressant-like effects in rats, without affecting male or female sexual behavior.Psychopharmacology · 2025Article
- Assessment of the Cardiovascular Risk of High-Fat-High-Fructose Diet in Hereditary Hypertriacylglycerolemic Rats and Venlafaxine Effect.Physiological research · 2024Article
- Gender differences in plasma S100B levels of patients with major depressive disorder.BMC psychiatry · 2024Article
- Evaluation of New Approaches to Depression Treatment Using an Animal Model of Pharmacoresistant Depression.International journal of molecular sciences · 2024Article
- The effects of venlafaxine on depressive-like behaviors and gut microbiome in cuprizone-treated mice.Frontiers in psychiatry · 2024Article
- Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories.Frontiers in psychiatry · 2023Review
- Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders.Scientific reports · 2021Article
- Article
- Interleukin-17 induced by cumulative mild stress promoted depression-like behaviors in young adult mice.Molecular brain · 2021Article
- Plasma Levels of Brain-Derived Neurotrophic Factor and S100B in Relation to Antidepressant Response to Ketamine.Frontiers in neuroscience · 2021Article
- Venlafaxine Mitigates Depressive-Like Behavior in Ovariectomized Rats by Activating the EPO/EPOR/JAK2 Signaling Pathway and Increasing the Serum Estradiol Level.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019Article
- Antibiotic Abuse Induced Histopathological and Neurobehavioral Disorders in Mice.Current drug safety · 2019Article
- S100B Levels in Patients with Type 2 Diabetes Mellitus and Co-Occurring Depressive Symptoms.Depression research and treatment · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccumulating evidence has indicated that S100B may be involved in the pathophysiology of depression. No published study has examined the effect of the antidepressant drug venlafaxine on S100B in animal models of depression. This study investigated S100B expression in the hippocampus and assessed the effect of venlafaxine on S100B mRNA level and protein expression in rats exposed to chronic unpredictable mild stress (CUMS).
methodsForty Sprague-Dawley rats were randomly divided into four groups as control, 0, 5 and 10 mg venlafaxine groups. The venlafaxine groups were exposed to CUMS from day 2 to day 43. Venlafaxine 0, 5 and 10 mg/kg were then administered from day 23 to day 43. We performed behavioral assessments with weight change, open-field and sucrose preference, and analyzed S100B protein expression and mRNA level in the hippocampus.
resultsThe CUMS led to a decrease in body weight, locomotor activity and sucrose consumption, but venlafaxine treatment (10 mg) reversed these CUMS-induced decreases Also, CUMS increased S100B protein expression and mRNA level in the hippocampus, but venlafaxine treatment (10 mg) significantly decreased S100B protein expression and mRNA level, which were significantly lower than the other treatment groups, without significant difference between the 10 mg venlafaxine and the control groups.
conclusionsOur findings showed that venlafaxine treatment (10 mg) may improve the depression-like behaviors and decrease over-expression of S100B protein and mRNA in the hippocampus in a rat model of depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.